Akebia Therapeutics (AKBA) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Akebia Therapeutics

NasdaqCM•Healthcare•Drug Manufacturers - Specialty & Generic

$0.90-0.02(-0.02%)Market open

Market Cap

$247.50M

P/S

1.1x

P/B

9.9x

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090, which is in Phase 2 clinical trial for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries; Vafseo License and Collaboration Agreements; CSL Vifor Agreements; Averoa License Agreement; License Agreement with Panion & BF Biotech, Inc.; Cyclerion Therapeutics License Agreement; and Q32 Asset Purchase Agreement. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

How this company scores

GoodMetricSide Score: 60/100

Strongest: Balance Sheet & Red Flags (19/25); weakest: Cash & Earnings Quality (13/25).

Profitability14/25

Growth14/25

Balance Sheet & Red Flags19/25

Cash & Earnings Quality13/25

Strengths

Long cash runwayProfit converts from growthImproving leverageConsistent growth

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 1.1x5y range 0.2x – 4.7x

Currently near its 20-quarter median.

P/B · 9.9x5y range 1.1x – 32.7x

Currently near its 12-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 4 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $247.50M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $219.06M
Q. Revenue: $49.13M
TTM EBITDA: $-15.13M
TTM Op. Income: $-15.13M
Q. Op. Income: $-6.33M
TTM Net Income: $-29.67M
Q. Net Income: $-8.91M
EPS: $-0.03
Shares Out.: $269.60M

$219.06M in TTM revenue grew 7.5% YoY, reaching $49.13M last quarter. TTM EBITDA of $-15.13M and TTM operating income of $-15.13M show growth is flowing through to the bottom line. However, net income is negative at $29.67M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has fallen for 2 consecutive quarters — a weakening trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 78.8%
EBITDA Margin: -12.9%
Op. Margin: -12.9%
Net Margin: -18.1%

Op. margin of -12.9% is down 35.4% YoY — costs are rising relative to revenue. Net margin at -18.1% and gross margin of 78.8% show how much of each revenue dollar survives to profit. Over the past year, operating margin is down 157% — a weakening trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 1.1x
P/B Ratio: 9.9x

P/S of 1.1x and P/B of 9.9x. P/S is low relative to typical market levels.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $349.66M
Cash: $155.55M
Long-Term Debt: $24.75M
Book Value: $25.02M
D/E Ratio: 1.0
Debt/EBITDA: N/A

With $349.66M in assets and $24.75M in long-term debt, D/E is 1.0and book value is $25.02M — a conservative capital structure with a cushion to weather downturns. Across the last 6 quarters, debt/equity has fallen for 2 consecutive quarters — an improving trend.

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $3.52M
TTM Free Cash Flow: $40.26M
FCF Margin: 18.4%
FCF / Net Income: -1.4

TTM FCF of $40.26M on $3.52M in operating cash flow. The FCF / Net Income ratio of -1.4x means the business consumes cash — it is not yet self-funding. Across the last 8 quarters, free cash flow has fallen for 2 consecutive quarters — a weakening trend.